Abstract
Infectious disease treatment and immunisation have undergone a transformative change in recent years. With the advancement of biotechnology and genetic engineering, a large number of disease-specific biological have been created, as well as a focus on delivering these biological effectively. Niosomes are vesicular Nano carriers that are gaining popularity as a potential transdermal drug delivery system due to properties like enhanced drug penetration, a local depot for sustained drug release, and a rate-limiting membrane for modulating systemic absorption of drugs through the skin. Niosomes are non-ionic surfactant-based vesicles that are biodegradable, relatively nontoxic, more stable, and less expensive than liposomes. This analysis gives a high-level overview of niosomes, including their chemical composition, structure, benefits, and applications, as well as some general observations on niosomes as percutaneous permeation enhancers.
Highlights
1.2 Non-ionic SurfactantsTargeted drug delivery is a concept that aims to concentrate a drug in the tissues of interest while lowering the relative concentration
While niosomes have been tried for a variety of routes, they are most commonly used for the transdermal route (Novasome Products Such as 30 percent Petrolatum Novasomes and 10 percent Salicylic Acid Novasomes)
When non-ionic surfactants are mixed into niosomes, the skin tolerates them much better than when they are used in an emulsion
Summary
Targeted drug delivery is a concept that aims to concentrate a drug in the tissues of interest while lowering the relative concentration. Niosomes are vesicular Nano carriers that have gotten a lot of attention because of their unique properties. They have amphiphilic molecules in a lamellar (bilayer) structure surrounded by an aqueous compartment. Contain both hydrophobic (tails) and hydrophilic (heads) classes and are selfassembling, aggregating into a variety of shapes like micelles or into a planar lamellar bilayer [2]. It can be used to distribute medications It improves bioavailability by crossing the gastrointestinal tract's anatomical barrier through transcytosis of Peyer's 1 M cells of a payer’s patches in the intestinal lymphatic tissues [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
